 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
*Section of Nephrology, The University of Chicago, Chicago, Illinois; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Rheumatology, University of Colorado Health Sciences Center, Denver, Colorado.
Correspondence to Dr. Richard J. Quigg, Section of Nephrology, The University of Chicago, 5841 S. Maryland Ave., MC5100, Chicago, IL 60637. Phone: 773-702-0757; Fax: 773-702-4816;
ABSTRACT. Complement receptor 1-related gene/protein y (Crry) in rodents is a potent membrane complement regulator that inhibits complement C3 activation by both classical and alternative pathways. To clarify the role of complement in lupus nephritis, MRL/lpr mice were given Crry as a recombinant protein (Crry-Ig) from 12 to 24 wk of age. Control groups were given saline or normal mouse IgG. Sera and urine were collected biweekly. Only 1 of 20 (5%) Crry-Ig-treated mice developed renal failure (BUN > 50 mg/dl) compared with 18 of 38 (47.4%) mice in control groups (P = 0.001). BUN levels at 24 wk were reduced from 68.8 ± 9.7 mg/dl in control groups to 38.5 ± 3.9 mg/dl in the Crry-Ig-treated group (P < 0.01). Urinary albumin excretion at 24 wk was also significantly reduced from 5.3 ± 1.4 mg/mg creatinine in the control groups to 0.5 ± 0.2 mg/mg creatinine in the Crry-Ig-treated group (P < 0.05). Of the histologic data at 24 wk, there was a significant reduction in scores for glomerulosclerosis and C3d, IgG, IgG3, and IgA staining intensity in glomeruli in complement-inhibited animals. Crry-Ig-treated animals were also protected from vasculitic lesions. Although there was no effect on relevant autoimmune manifestations such as anti-double stranded DNA titers or cryoglobulin IgG3 levels, circulating immune complex levels were markedly higher in complement-inhibited animals. Thus, inhibition of complement activation with Crry-Ig significantly reduces renal disease in MRL/lpr lupus mice. The data support the strategy of using recombinant complement C3 inhibitors to treat human lupus nephritis. E-mail: rquigg@medicine.uchicago.edu
This article has been cited by other articles:
 |
|
 |
|
  C. Atkinson, F. Qiao, H. Song, G. S. Gilkeson, and S. Tomlinson Low-Dose Targeted Complement Inhibition Protects against Renal Disease and Other Manifestations of Autoimmune Disease in MRL/lpr Mice J. Immunol., January 15, 2008; 180(2): 1231 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Song, F. Qiao, C. Atkinson, V. M. Holers, and S. Tomlinson A Complement C3 Inhibitor Specifically Targeted to Sites of Complement Activation Effectively Ameliorates Collagen-Induced Arthritis in DBA/1J Mice J. Immunol., December 1, 2007; 179(11): 7860 - 7867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nangaku A Crry for polar shedding Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1773 - 1775. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Farrar, W. Zhou, T. Lin, and S. H. Sacks Local extravascular pool of C3 is a determinant of postischemic acute renal failure FASEB J, February 1, 2006; 20(2): 217 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Thurman and V. M. Holers The Central Role of the Alternative Complement Pathway in Human Disease J. Immunol., February 1, 2006; 176(3): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Alexander, A. Jacob, L. Bao, R. L. Macdonald, and R. J. Quigg Complement-Dependent Apoptosis and Inflammatory Gene Changes in Murine Lupus Cerebritis J. Immunol., December 15, 2005; 175(12): 8312 - 8319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Wenderfer, B. Ke, T. J. Hollmann, R. A. Wetsel, H. Y. Lan, and M. C. Braun C5a Receptor Deficiency Attenuates T Cell Function and Renal Disease in MRLlpr Mice J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3572 - 3582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, I. Osawe, M. Haas, and R. J. Quigg Signaling through Up-Regulated C3a Receptor Is Key to the Development of Experimental Lupus Nephritis J. Immunol., August 1, 2005; 175(3): 1947 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Cunningham and R. J. Quigg Contrasting Roles of Complement Activation and Its Regulation in Membranous Nephropathy J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1214 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Watanabe, A. J. Mamelak, E. Weiss, B. Wang, I. Freed, A. K. Brice, L. Wachtman, K. L. Gabrielson, N. Yokota, D. J. Hicklin, et al. Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model Clin. Cancer Res., January 1, 2005; 11(1): 407 - 409. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Alexander, M. C. Pickering, M. Haas, I. Osawe, and R. J. Quigg Complement Factor H Limits Immune Complex Deposition and Prevents Inflammation and Scarring in Glomeruli of Mice with Chronic Serum Sickness J. Am. Soc. Nephrol., January 1, 2005; 16(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Quigg Complement and the Kidney J. Immunol., October 1, 2003; 171(7): 3319 - 3324. [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, J. Zhou, V. M. Holers, and R. J. Quigg Excessive Matrix Accumulation in the Kidneys of MRL/lpr Lupus Mice Is Dependent on Complement Activation J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2516 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nangaku Complement Regulatory Proteins: Are They Important in Disease? J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2411 - 2413. [Full Text] [PDF]
|
|
|
|
|
|
W. G. Couser Complement Inhibitors And Glomerulonephritis: Are We There Yet? J. Am. Soc. Nephrol., March 1, 2003; 14(3): 815 - 818. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
